BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Overall, the attraction of Pfizer as an investment is its level of diversification with several different growing drug ...

WASHINGTON--Drugmaker Merck asked U.S. regulators Monday ... first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

Merck & Co. Inc.’s stock rose 1.4% premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, offsetting lowered guidance due to deals with partners Curon ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...